August 2012
-
AstraZeneca has announced that the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) has voted to recommend the use of FluMist Quadrivalent intranasal live Influenza vaccine for the 2018-19 flu… Read more . . .
-
Lonza has announced the installation of a new Harro Hӧfliger Modu-C MS encapsulation unit at its product development and manufacturing facility in Tampa, FL. The company said that installation and validation of the unit are… Read more . . .
-
The US Patent and Trademark Office has issued US Patent Number 9,895,385, titled “Methods for treating pulmonary non-tuberculous mycobacterial infections” to Insmed Incorporated, the company said. According to Insmed, the patent is the 9th for… Read more . . .
-
Molins PLC, the parent company of automated filling and packaging company Molins Technologies, has announced a name change to Mpac Group. All of the businesses in the group will now be joined into a single… Read more . . .
-
The FDA has accepted Acorda Therapeutics’ revised NDA for Inbrija inhaled levodopa for the treatment of symptoms associated with OFF periods in Parkinson’s disease in patients taking carbidopa/levodopa, the company said. The PDUFA target date… Read more . . .
-
GSK has voluntarily recalled one lot of Ventolin Diskus 200 μg salbutamol (albuterol) DPIs in Canada due to “a manufacturing issue that may result in a small number of Ventolin Diskus devices not delivering the… Read more . . .
-
GlaxoSmithKline and Innoviva have announced the submission of a type II variation application seeking expanded use for the Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) DPI for the treatment of COPD. Trelegy Ellipta was granted marketing authorization… Read more . . .
-
Sanner Ventures and Amiko Digital Health have announced a deal in which Sanner will make a strategic investment in further development of Amiko’s Respiro dry powder inhaler monitoring platform. Amiko also announced that the Respiro… Read more . . .
-
Opiant Pharmaceuticals has announced that, based on feedback from the FDA and positive data from a Phase I clinical study, the company plans to pursue a 505(b)(2) development path for its OPNT003 intranasal nalmefene for… Read more . . .
-
Teva Pharmaceutical Industries has announced the US launch of its QVAR RediHaler beclomethasone dipropionate HFA MDI, which was approved by the FDA in August 2017 for the treatment of asthma in patients aged 4 years… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.